Finding Your Target: Biomarker-Guided Adaptive Trial Design in Immuno-oncology

In the field of immuno-oncology, the heterogeneity of patient responses to treatments is well documented and can play an important role in determining the clinical benefits of new therapies. In this white paper, see how a significant advance towards mitigating the impact of this has been the increased use of predictive biomarkers, often as a central part of the clinical trial design, to identify the target patient population that will potentially derive maximal clinical benefit from a new treatment.